Bonk, Inc 8-K, filed Aug 16, 2022
Bonk, Inc. (BNKK)
About this 8-K
Bonk, Inc filed this 8-K on August 16, 2022.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C., 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
(The Nasdaq Capital Market) | ||||
(The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure
On August 16, 2022, the Jupiter Wellness, Inc. (the “Company”) issued a press release (the “Press Release”) to announce the Company’s financial results for the second quarter ended June 30, 2022, and provided an overview of recent operational highlights. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated August 16, 2022 | |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 16, 2022
| JUPITER WELLNESS, INC. | ||
| By: | /s/ Brian John | |
| Brian John | ||
| Chief Executive Officer | ||
Exhibit 99.1
| FINAL FOR RELEASE |  |
| Contact | |
| Jupiter Wellness, Inc. | |
| 561-244-7100 | |
| investors@jupiterwellness.com | |
Release Date |
|
August 16, 2022 |
Jupiter Wellness Reports Second Quarter 2022 Financial Results and Operational Highlights
Minoxidil Booster Licensed to Taisho Pharmaceutical for the Japanese market.
No Stingz Jellyfish Protectant SPF sunscreen launched
$3,000,582 in Revenues for the three months ended June 30, 2022
JUPITER, FL / July 16, 2022 – Jupiter Wellness, Inc. (Nasdaq: JUPW) today announced financial results for the second quarter ended June 30, 2022, and provided an overview of recent operational highlights.
Recent Highlights—Corporate
In June 2022, Jupiter Wellness announced they licensed SULT1A1 minoxidil booster to Taisho Pharmaceutical Co. Ltd (TYO:4581) for the Japanese market. Taisho Pharmaceutical, the largest minoxidil manufacturer, and a leader in hair therapies, in Japan is now planning to support hair loss patients with this breakthrough adjuvant therapy to topical minoxidil. The minoxidil (sulfotransferase enzyme) booster (SULT1A1) was acquired by Jupiter Wellness in an acquisition of assets that included issued patents, patent applications, products, clinical trial results, and licensing agreements from Applied Biology.
In April 2022, Jupiter introduced - NoStingz, sunscreen which in addition to protection against the Sun, it protects against jellyfish and man o’ war stings and sea lice, all while continuing to protect ocean lovers’ from UVA/UVB in a range of SPFs. Jupiter signed a license agreement with Shark Defense Technologies for the exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds including 4 patents pending.
| 1 |
Second Quarter 2022 Financial Results
Revenues
We generated $3,000,582 in revenues for the three months ended June 30, 2022 compared to $595,088 revenues in the three months ended June 30, 2021, we are now experiencing a greater demand for our products.
Operating Expenses
We had total operating expenses and other income and expense of $1,945,999 for the three months ended June 30, 2022 compared to $4,332,249 for the three months ended June 30, 2021.
Income/Losses
Net losses were $1,440,856 for the three months ended June 30, 2022 compared to $4,151,074 for the three months ended June 30, 2021.
“I am pleased to report that Jupiter Wellness is on track with its 2022 roadmap. Jupiter finished the first half of 2022 with momentum and our strongest revenue numbers to date” said Brian John, CEO of Jupiter Wellness.”
About Jupiter Wellness
Jupiter Wellness researches, develops, licenses, and sells various products in the wellness field focused on hair, skin, and sexual health. Its PhotocilTM, Minoxidil Booster, and NoStingz are currently sold and licensed to sell in over 30 countries worldwide. For more information, please visit www.JupiterWellness.com.
Media Contact
Phone: 561-244-7100
Email: media@JupiterWellness.com
Investor Contact
Phone: 561-244-7100
Email: investors@jupiterwellness.com
Forward-Looking Statements
This communication contains forward-looking statements regarding Jupiter Wellness, including, the anticipated timing of studies and the results and benefits thereof. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the Company’s current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties, many of which are beyond Jupiter Wellness’ control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties and other risks and uncertainties affecting Jupiter Wellness, including those described from time to time under the caption “Risk Factors” and elsewhere in Jupiter Wellness’ Securities and Exchange Commission (SEC) filings and reports, including Jupiter Wellness’ Annual Report on Form 10-K for the year ended December 31, 2021, and future filings and reports by Jupiter Wellness. Moreover, other risks and uncertainties of which the combined company is not currently aware may also affect each of the companies’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events at such dates, even if they are subsequently made available by Jupiter Wellness on its website or otherwise. Jupiter Wellness undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date on which the forward-looking statements were made.
###
| 2 |